TSU-Pr1 人前列腺癌細胞
Catalogue No.: C1418
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%1640+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

anti-tumor immune response. It has been approved by the Food and Drug Administration (FDA) for the treatment of various tumor types, including melanoma, non-small cell lung cancer (NSCLC), head ａnd necksquamous cell carcinoma (HNSCC), and urothelial cancer (5). Clinical trials of ICB are currently being evaluated in NEN derived from different origins, including the gastrointestinal tract (GI), pancreas, and lung (6–9). In the phase II KEYNOTE-158 study, anti-PD-1